Scalper1 News
The market may have emerged from a correction last week, but a look at the top (and bottom) industry groups reveals a defensive slant. As of Wednesday’s IBD, five medical groups made not just the top 20 — but the top 10. Biotechs claimed the No. 2 spot, ethical drugs No. 3, systems and equipment No. 5, generic drugs No. 7, and research equipment/services No. 10. The No. 9 group, Computer Software-Medical, is a related play. Ethical and generic Scalper1 News
Scalper1 News